Critical Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. Zura Bio (NASDAQ:ZURA)

Taysha Gene Therapies (NASDAQ:TSHA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Profitability

This table compares Taysha Gene Therapies and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-1,790.06%	-118.08%
Zura Bio	N/A	-110.19%	-28.68%

Risk and Volatility

Taysha Gene Therapies has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares Taysha Gene Therapies and Zura Bio’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.60 million	43.03	-$166.01 million	($2.29)	-0.97
Zura Bio	N/A	N/A	$3.55 million	N/A	N/A

Zura Bio has lower revenue, but higher earnings than Taysha Gene Therapies.

Institutional & Insider Ownership

25.9% of Taysha Gene Therapies shares are held by institutional investors. 2.3% of Taysha Gene Therapies shares are held by insiders. Comparatively, 15.8% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Taysha Gene Therapies and Zura Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	0	4	8	0	2.67
Zura Bio	0	0	4	1	3.20

Taysha Gene Therapies presently has a consensus target price of $7.91, indicating a potential upside of 257.07%. Zura Bio has a consensus target price of $16.60, indicating a potential upside of 235.35%. Given Taysha Gene Therapies’ higher probable upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Zura Bio.

Summary

Zura Bio beats Taysha Gene Therapies on 7 of the 11 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.